Premium
Translational pharmacology of TD139, an inhaled small molecule galectin‐3 (Gal‐3) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF)
Author(s) -
Slack R. J.,
Hirani N.,
Gibbons M. A.,
Simpson A.J.,
Ford P.,
Leffler H.,
Nilsson U. J.,
Sethi T.,
Pedersen A.,
Schambye H.,
Maher T.M.,
MacKin A. C.
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.02311
Subject(s) - medicine , bronchoalveolar lavage , idiopathic pulmonary fibrosis , in vivo , bleomycin , ex vivo , tolerability , pharmacokinetics , pharmacology , lung , pharmacodynamics , galectin 3 , pathology , immunology , chemotherapy , adverse effect , microbiology and biotechnology , biology